ResApp Health Limited (ASX: RAP), the developer of smartphone medical applications for the diagnosis and management of respiratory disease, is pleased to announce that Dr Udantha Abeyratne, Associate Professor in Biomedical Engineering at The University of Queensland and Chief Scientific Advisor at ResApp Health, has been invited to present ResApp’s pneumonia diagnostic technology at the inaugural Pushing the Pace: The Pneumonia Innovations Summit to be held on November 12th, 2015 in New York City.
The Summit, held on World Pneumonia Day and supported by UNICEF, will bring together the growing community of innovators with new and improved technologies for the prevention, diagnosis and treatment of childhood pneumonia in low resource settings. Pneumonia is the leading infectious disease killer of children, claiming the lives over 900,000 children under five every year, the vast majority in South Asia and sub-Saharan Africa.
“This is a fabulous opportunity for Dr Abeyratne to showcase our technology to a prestigious audience attended by industry participants including non-governmental organisations, investors and United Nations agencies,” said Dr Tony Keating, CEO and Managing Director of ResApp Health. “Working with global aid and humanitarian organisations to deliver tools for low-cost diagnosis in the developing world is one of the three target markets for the commercialisation of the ResApp technology.”
Dr Abeyratne commented, “This meeting provides an excellent platform to present our technology to global stakeholders at the forefront of managing childhood pneumonia in low resource settings. These groups see the crucial role innovations with great lifesaving potential can play in reducing pneumonia fatalities to the levels required by the United Nation’s new Sustainable Development Goals.”
The Pneumonia Innovations Summit is an initiative of the Pneumonia Innovations Team, a global network of more than 200 organisations and individuals committed to accelerating the development and adoption of new technologies with the greatest potential to reduce child deaths from pneumonia, particularly in the countries where deaths are concentrated. The Team works in support of the UN Secretary-General’s Every Woman, Every Child movement, and is chaired by the MDG Health Alliance and PATH.
ResApp recently released positive preliminary results from the clinical study currently underway at Joondalup Health Campus and Princess Margaret Hospital in Perth, Western Australia. From a 211 patient dataset, greater than 95% accuracy was obtained for distinguishing asthma patients from healthy subjects and pneumonia patients from healthy subjects based solely on analysing a patient’s cough on a smartphone in comparison to the hospital diagnosis. By the end of this calendar year, ResApp expects to have over 400 patients enrolled in the study and conduct a Pre-Submission Meeting with the FDA.
– ENDS –
About ResApp Health Limited
Founded in 2014, ResApp Health Limited, through an exclusive license granted by the University of Queensland (UQ) is developing smartphone medical applications for the diagnosis and management of respiratory disease. The technology is based on a machine learning algorithm that uses sound alone without the need for additional hardware to diagnose and measure the severity of a respiratory condition. The algorithms have been successfully tested for pneumonia and asthma diagnosis in a clinical proof of concept study by UQ through funding from the Bill and Melinda Gates Foundation. Addressable markets for this technology include licensing to large telehealth service providers for ‘in consultation’ point of care diagnosis, at-home diagnosis and management of respiratory disease through direct sales to consumers and healthcare providers, and working with global aid and humanitarian organisations to deliver tools for low-cost diagnosis in the developing world.
ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000
© 2020 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries. ResAppDx is not available for sale in the United States.